Mar 16, 2023
This article was originally published by The Defender - Children's Health Defense's News & Views Website. (Children's Health Defense) - Infants and children six months through age four who received the three-dose primary series of the Pfizer-BioNTech COVID-19 vaccine are now eligible for a fourth dose - Pfizer's bivalent booster shot. The U.S. Food and Drug Administration (FDA) on Tuesday amended the Emergency Use Authorization (EUA) of Pfizer bivalent COVID-19 booster vaccine for the younger age group, but only for those children who received the three-dose series before the FDA authorized Pfizer's bivalent omicron booster as the third shot in the primary series. Under the amended authorization, children can receive their fourth shot two months after completing the three-dose primary series. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research, said the authorization gave parents the opportunity to "update their chil